Richard Mullvain, RPh, BCPS (AQC), CCCC, a cardiovascular clinical pharmacist and expert in cardiovascular care at the Essentia Health Heart & Vascular Center in Duluth, Minnesota, delivered a focused ...
THOUSAND OAKS, Calif., Amgen today announced the submission of an application to the U.S. Food and Drug Administration (FDA) seeking approval of a single-dosing option for the monthly administration ...
At today's FDA advisory committee meeting, Amgen will present Repatha clinical trial data from approximately 6,800 patients, including more than 4,500 patients with high cholesterol in 10 Phase 3 ...
THOUSAND OAKS, Calif., March 20, 2015 -- Amgen (NASDAQ: AMGN) today announced that an application seeking marketing approval of RepathaTM (evolocumab) for the treatment of high cholesterol has been ...
The FDA grants Priority Review for Amgen's (NASDAQ:AMGN) supplemental Biologics License Application (sBLA) seeking approval to add the risk reduction of major cardiovascular events (the FOURIER study) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback